Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy
https://doi.org/10.22416/1382-4376-2022-32-4-95-103
Abstract
Aim: to review the common risk factors and links in the pathogenesis of functional gastrointestinal disorders (FGID) to optimize therapy of patients with a combination of multiple FGID.
Key points. FGID occurs in more than 40 % of people globally, mainly affecting the working-age population in young and middle-aged subjects. At the same time, more than 30 % of patients have a combination of 2 or more functional gastrointestinal (GI) disorders i.e. overlap syndrome. Common links in the pathogenesis of FGID include disorders of gut-brain interaction, visceral hypersensitivity, changes in intestinal microbiota, overproduction of proinflammatory cytokines, impaired epithelial permeability and motor activity of the gastrointestinal tract. The combination of FGID in various gastrointestinal segments is associated with more pronounced clinical symptoms (mutual burden syndrome). Common risk factors and pathogenetic links of the functional disorders enables reducing the number of prescribed medications when several FGIDs overlap in one patient, which also increases adherence to therapy. Treatment of FGID includes adjustment of risk factors and drug therapy. As a pathogenetically justified pharmacotherapy of overlap syndrome, Kolofort, highly diluted antibodies to TNF-α, histamine and brain-specific protein S-100, is of interest.
Conclusion. Kolofort has demonstrated high efficacy and safety including among patients with overlap FGID enabling to consider it as the treatment of choice in these patients.
About the Authors
S. N. Mekhdiyev
First St. Petersburg State Medical University named after Academician I.P. Pavlov;
Gastroenterological Center “Expert” LLC
Sabir N. Mekhdiyev — Dr. Sci. (Med.), Professor of the Department of Hospital Therapy with the course of Allergology and Immunology named after Academician M.V. Chernorutsky; chief physician
197022, St. Petersburg, Lev Tolstoy str., 6–8;
197110, St. Petersburg, Pionerskaya str., 16
O. A. Mekhdieva
First St. Petersburg State Medical University named after Academician I.P. Pavlov;
Gastroenterological Center “Expert” LLC
Olga A. Mekhdieva — Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy with a course of allergology and Immunology named after Academician M.V. Chernorutsky; gastroenterologist
197022, St. Petersburg, Lev Tolstoy str., 6–8;
197110, St. Petersburg, Pionerskaya str., 16
O. M. Berko
Gastroenterological Center “Expert” LLC
Russian Federation
Russian Federation
Olesya M. Berko — gastroenterologist
197110, St. Petersburg, Pionerskaya str., 16
References
1. Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi: 10.1053/j.gastro.2020.04.014
2. Sperber A.D., Freud T., Aziz I., Palsson O.S., Drossman D.A., Dumitrascu D.L., et al. Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clin Gastroenterol Hepatol. 2022;20(5):e945–e956. doi: 10.1016/j.cgh.2021.05.042
3. Selivanova G.B. , Poteshkina N.G. Functional Disorders of the Biliary Tract in Clinical Practice: Modern Aspects of Diagnosis and Management of Patients. Lechebnoe delo. 2017;3:11–17. (In Russ.)
4. Drossman D.A., Tack J. Rome Foundation Clinical Diagnostic Criteria for Disorders of Gut-Brain Interaction. Gastroenterology. 2022;162(3):675–679. doi: 10.1053/j.gastro.2021.11.019
5. Golovanova E.V. Functional gastrointestinal disturbances: ways to psychosomatic correction. RMJ. 2019;5:24–29. (In Russ.)
6. Ford A.C., Marwaha A., Lim A., Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401–409. doi: 10.1016/j.cgh.2009.07.020
7. Talley N.J., Zinsmeister A.R., Schleck C.D., Melton L.J. 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102(4 Pt 1):1259–1268.
8. Futagami S., Yamawaki H., Shimpuku M., Izumi N., Wakabayashi T., Kodaka Y., et al. Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia. J Nippon Med Sch. 2013;80(5):362–370. doi: 10.1272/jnms.80.362
9. McNally M.A., Locke G.R., Zinsmeister A.R., Schleck C.D., Peterson J., Talley N.J. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334–343. doi: 10.1111/j.1365-2036.2008.03715.x
10. Osipenko M.F., ButGusaim V.I., Voloshina N.B., Bicbulatova E.A. “Overlap syndrome” irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal. 2008;(5):21–26. (In Russ.)
11. Polunina T.E. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Meditsinskiy Sovet. 2020;(15):28–38. doi: 10.21518/2079-701X-2020-15-28-38 (In Russ.)
12. Matsuzaki J., Suzuki H., Asakura K., Fukushima Y., Inadomi J.M., Takebayashi T., et al. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil. 2012;24(4):325–e164. doi: 10.1111/j.1365-2982.2011.01859.x
13. Ottillinger B., Storr M., Malfertheiner P., Allescher H.D. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3-4):65–72. doi: 10.1007/s10354-012-0169-x
14. Fujiwara Y., Kubo M., Kohata Y., Machida H., Okazaki H., Yamagami H., et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med. 2011;50(21):2443–2447. doi: 10.2169/internalmedicine.50.6012
15. Vakil N., Stelwagon M., Shea E.P., Miller S. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J. 2016;4(3):413–422 doi: 10.1177/2050640615600114
16. Choung R.S., Richard Locke G. 3rd, Schleck C.D., Zinsmeister A.R., Talley N.J. Multiple functional gastrointestinal disorders linked to gastroesophageal reflux and somatization: A population-based study. Neurogastroenterol Motil. 2017;29(7):10.1111/nmo.13041. doi: 10.1111/nmo.13041
17. Fikree A., Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44–52. doi: 10.7861/clinmed.2020-0980
18. Fichna J., Storr M.A. Brain-Gut Interactions in IBS. Front Pharmacol. 2012;3:127. doi: 10.3389/fphar.2012.00127
19. Farmer A.D., Aziz Q. Mechanisms of visceral pain in health and functional gastrointestinal disorders. Scand J Pain. 2014;5(2):51–60. doi: 10.1016/j.sjpain.2014.01.002
20. Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Cibert-Goton V., Alpizar Y.A., et al. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology. 2016;150(4):875–87.e9. doi: 10.1053/j.gastro.2015.12.034
21. Cryan J.F., O'Riordan K.J., Cowan C.S.M., Sandhu K.V., Bastiaanssen T.F.S., Boehme M., et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877–2013. doi: 10.1152/physrev.00018.2018
22. Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042–1054.e1. doi: 10.1053/j.gastro.2016.12.039
23. Simrén M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176. doi: 10.1136/gutjnl-2012-302167
24. Pusceddu M.M., Gareau M.G. Visceral pain: gut microbiota, a new hope?. J Biomed Sci. 2018;25(1):73. doi:10.1186/s12929-018-0476-7
25. Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., et al. The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome. Gut Liver. 2009;3(3):174–179. doi: 10.5009/gnl.2009.3.3.174
26. Martínez C., Lobo B., Pigrau M., Ramos L., González-Castro A.M., Alonso C., et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62(8):1160–1168. doi: 10.1136/gutjnl-2012-302093
27. Bertiaux-Vandaële N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 2011;106(12):2165–2173. doi: 10.1038/ajg.2011.257
28. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016;1(3):135–145. doi: 10.1159/000447252
29. Peters S.A., Edogawa S., Sundt W.J., Dyer R.B., Dalenberg D.A., Mazzone A., et al. Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. Am J Gastroenterol. 2017;112(6):913–923. doi: 10.1038/ajg.2017.48
30. Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita Å.V., et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262–271. doi: 10.1136/gutjnl-2012-303857
31. Talley N.J., Ford A.C. Functional Dyspepsia. N Engl J Med. 2015;373(19):1853–1863. doi: 10.1056/NEJMra1501505
32. Talley N.J. Functional Dyspepsia: Advances in Diagnosis and Therapy. Gut Liver. 2017;11(3):349–357. doi: 10.5009/gnl16055
33. Mitselou A., Grammeniatis V., Varouktsi A., Papadatos S.S., Katsanos K., Galani V. Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease. Intest Res. 2020;18(1):115–120. doi: 10.5217/ir.2019.00125
34. Norlin A.K., Walter S., Icenhour A., Keita Å.V., Elsenbruch S., Bednarska O., et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-α and mesocorticolimbic connectivity. Brain Behav Immun. 2021;92:211–222. doi: 10.1016/j.bbi.2020.11.035
35. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409–416. doi: 10.1007/s10555-006-9005-3
36. Zhu G., Du Q., Wang X., Tang N., She F., Chen Y. TNF-α promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. Int J Mol Med. 2014;33(6):1431–1440. doi: 10.3892/ijmm.2014.1711
37. Du Q., Jiang L., Wang X., Wang M., She F., Chen Y. Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C. Cancer Sci. 2014;105(10):1261–1271. doi: 10.1111/cas.12504
38. Alotaibi A.G., Li J.V., Gooderham N.J. Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology. 2021;457:152806. doi: 10.1016/j.tox.2021.152806
39. Pakhomova I.G. Gut dysmotility in functional gastrointestinal disorders. Potential for therapeutic adjustment in terms of clinical case management. Meditsinskiy sovet = Medical Council. 2020;(5):18–23. doi: 10.21518/2079-701X-2020-5-18-23. (In Russ.)
40. Kanazawa F., Mine K., Mishima N., Muraoka M., Nakagawa T. A study of the dynamics of gallbladder contraction in irritable bowel syndrome. Nippon Shokakibyo Gakkai Zasshi. 1992;89;1185–1190 (In Japanese)
41. Lee O.Y. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16(2):120–130. doi: 10.5056/jnm.2010.16.2.120
42. Guliter S., Yilmaz S., Yakaryilmaz F., Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-28):407–411.
43. Güçlü M., Pourbagher A., Serin E., Kul K., Ozer B., Cosar A., et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309–1312. doi: 10.1111/j.1440-1746.2006.04136.x
44. Ragnarsson G., Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol. 1998;10(5):415–421. doi: 10.1097/00042737-199805000-00011
45. Walker M.M., Salehian S.S., Murray C.E., Rajendran A., Hoare J.M., Negus R., et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther. 2010;31(11):1229–1236. doi: 10.1111/j.1365-2036.2010.04282.x
46. Fritscher-Ravens A., Pflaum T., Mösinger M., Ruchay Z., Röcken C., Milla P.J., et al. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology. 2019;157(1):109–118.e5. doi: 10.1053/j.gastro.2019.03.046
47. Pilichiewicz A.N., Feltrin K.L., Horowitz M., Holtmann G., Wishart J.M., Jones K.L., et al. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol. 2008;103(10):2613–2623. doi: 10.1111/j.1572-0241.2008.02041.x
48. Keshteli A.H., Feizi A., Esmaillzadeh A., Zaribaf F., Feinle-Bisset C., Talley N.J., et al. Patterns of dietary behaviours identified by latent class analysis are associated with chronic uninvestigated dyspepsia. Br J Nutr. 2015;113(5):803–812. doi: 10.1017/S0007114514004140
49. Stanghellini V., Chan F.K., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–1392. doi: 10.1053/j.gastro.2016.02.011
50. Göktaş Z., Köklü S., Dikmen D., Öztürk Ö., Yılmaz B., Asıl M., et al. Nutritional habits in functional dyspepsia and its subgroups: a comparative study. Scand J Gastroenterol. 2016;51(8):903–907. doi: 10.3109/00365521.2016.1164238
51. Volta U., Caio G., Karunaratne T.B., Alaedini A., De Giorgio R. Non-coeliac gluten/wheat sensitivity: advances in knowledge and relevant questions. Expert Rev Gastroenterol Hepatol. 2017;11(1):9–18. doi: 10.1080/17474124.2017.1260003
52. Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K., Belousova Ye.A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross z gastroenterol gepatol koloproktol. 2017;27(5):76–93. doi: 10.22416/1382-4376-2017-27-5-76-93 (In Russ.)
53. Quigley E.M., Fried M., Gwee K.A., Khalif I., Hungin A.P., Lindberg G., et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704–713. doi: 10.1097/MCG.0000000000000653
54. Epstein O.I., Pashinsky V.G., Zelenskaya K.L., Povet'eva T.N. Anti-inflammatory and analgesic effect of a homeopathic preparation of antibodies to tumor necrosis factor-α. Bulletin of experimental biology and medicine. 2001;3:57–59. (In Russ.)
55. Krylova S.G., Razina T.G., Zueva E.P., Amosova E.N., Shilova N.V., Dugina Yu.L., et al. Analgesic and anti-inflammatory activity of antibodies to histamine in the experiment. Bulletin of experimental biology and medicine. 2002;4:95–97. (In Russ.)
56. Ertuzun I.A., Zueva E.P., Krylova S.G., Efimova L.A., Dugina J.L., Epstein O.I. Experimental study of Colofort, a new medicine for treatment of inflammatory bowel syndrome and other functional disorders of gastrointestinal tract. Vestnik VolgGMU. 2012;4:25–27 (In Russ.)
57. Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A., Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol. 2019;20(1):2. doi: 10.1186/s12876-019-1143-5
58. Maev I.V., Samsonov A.A., Yashina A.V., Andreev D.N., Shestakov V.A., Karaulov S.A. Clinical efficacy and safety of treatment regimens for irritable bowel syndrome (a comparative study). Consilium Medicum. 2016;18(8):19–26. (In Russ.)
Supplementary files
Review
For citations:
Mekhdiyev S.N., Mekhdieva O.A., Berko O.M. Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):95-103. https://doi.org/10.22416/1382-4376-2022-32-4-95-103
Views:
1539
Email this article 
